{"schema_version":"secwatch.filing_event.v1","accession":"0002023658-25-000107","form_type":"8-K","ticker":"BCAX","cik":"0002023658","company_name":"Bicara Therapeutics Inc.","filed_at":"2025-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:02:41.350747+00:00","generated_at":"2026-05-16T22:42:14.016502+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Bicara Therapeutics reports Q3 net loss of $36.3M, gets FDA Breakthrough Therapy Designation for ficerafusp alfa","bullets":["Net loss $36.3M in Q3 2025 vs $17.5M in Q3 2024; R&D expenses rose to $33.0M from $15.9M.","Cash, equivalents, investments $407.6M as of Sept 30, 2025; expected to fund operations into H1 2029.","FDA granted Breakthrough Therapy Designation for ficerafusp alfa + pembrolizumab in 1L HPV-negative R/M HNSCC.","Phase 1b data for 750mg weekly dose of ficerafusp alfa + pembrolizumab expected at ESMO Asia 2025.","Expanded management team: Jenna Cohen (Chief Corp Affairs), Tanya Green (Chief Dev Officer), Bill Schelman (VP)."],"urls":{"canonical":"https://secwatch.observer/filing/0002023658-25-000107","json":"https://secwatch.observer/filing/0002023658-25-000107.json","markdown":"https://secwatch.observer/filing/0002023658-25-000107.md","text":"https://secwatch.observer/filing/0002023658-25-000107.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000107/0002023658-25-000107-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2023658/000202365825000107/bcax-20251110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T22:42:14.016502+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}